Format

Send to

Choose Destination
Target Oncol. 2016 Dec;11(6):815-824.

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Author information

1
Strelitz Diabetes Research Center and Neuroendocrine Unit, Eastern Virginia Medical School, Strelitz Diabetes Center, Norfolk, VA, USA. vinikai@evms.edu.
2
Quality of Life Department, European Organization for Research and Treatment of Cancer, Brussels, Belgium.
3
Pfizer Inc, New York, NY, USA.
4
Seoul National University College of Medicine, Seoul, Korea.
5
Paoli-Calmettes Institute, Marseille, France.
6
The University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.
7
McGill University Hospital Center, Montreal, Canada.
8
Bad Berka Central Clinic, Bad Berka, Germany.
9
Pfizer Oncology, La Jolla, CA, USA.
10
Hôpital Beaujon, Clichy, France.

Abstract

OBJECTIVE:

The objective of this analysis was to compare patient-reported outcomes and health-related quality of life (HRQoL) in a pivotal phase III trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic neuroendocrine tumors (NCT00428597).

PATIENTS AND METHODS:

Patients received sunitinib 37.5 mg (n = 86) or placebo (n = 85) on a continuous daily-dosing schedule until disease progression, unacceptable adverse events (AEs), or death. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 at baseline, Day 1 of every 4-week cycle, and end of treatment or withdrawal. Changes ≥10 points on each scale or item were deemed clinically meaningful.

RESULTS:

Sunitinib had anti-tumor effects and improved progression-free survival (PFS) compared with placebo. The study was terminated early for this reason and because of more serious AEs and deaths with placebo. Baseline HRQoL scores were well balanced between study arms, and were generally maintained over time in both groups. In the first 10 cycles, there were no significant differences between groups in global HRQoL, cognitive, emotional, physical, role, and social functioning domains, or symptom scales, except for worsening diarrhea with sunitinib (p < 0.0001 vs. placebo). Insomnia also worsened with sunitinib (p = 0.0372 vs. placebo), but the difference was not clinically meaningful.

CONCLUSION:

With the exception of diarrhea (a recognized side effect), sunitinib had no impact on global HRQoL, functional domains, or symptom scales during the progression-free period. Hence, in patients with pancreatic neuroendocrine tumors, sunitinib provided a benefit in PFS without adversely affecting HRQoL.

PMID:
27924459
DOI:
10.1007/s11523-016-0462-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center